State-matched organoid models to fight pancreatic cancer

Michael Karl Melzer; Elodie Roger; Alexander Kleger

doi:10.1016/j.trecan.2022.03.003

State-matched organoid models to fight pancreatic cancer

Trends Cancer. 2022 Jun;8(6):445-447. doi: 10.1016/j.trecan.2022.03.003. Epub 2022 Mar 31.

Authors

Michael Karl Melzer¹, Elodie Roger², Alexander Kleger³

Affiliations

¹ Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany; Clinic of Urology, Ulm University Hospital, Ulm, Germany.
² Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
³ Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany. Electronic address: alexander.kleger@uni-ulm.de.

PMID: 35370114
DOI: 10.1016/j.trecan.2022.03.003

Abstract

As one of the deadliest cancers, pancreatic ductal adenocarcinoma (PDAC) requires sophisticated model systems to dissect disease onset, progression, and therapy resistance, as well as to personalize therapy. In recent years, patient- and pluripotent stem cell-derived organoids have become state-of-the-art systems to refine existing therapeutic strategies and deepen our knowledge of disease pathophysiology.

Keywords: organoids; pancreatic cancer; personalized medicine; stem cells.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Pancreatic Ductal* / genetics
Carcinoma, Pancreatic Ductal* / therapy
Humans
Organoids / pathology
Pancreatic Neoplasms* / genetics
Pancreatic Neoplasms* / pathology
Pancreatic Neoplasms* / therapy